middle.news
Cambium Bio Secures $2.17M Capital Raise and Strategic Deals to Propel Phase 3 Trials
5:01pm on Monday 27th of October, 2025 AEDT
•
Healthcare
Read Story
Cambium Bio Secures $2.17M Capital Raise and Strategic Deals to Propel Phase 3 Trials
5:01pm on Monday 27th of October, 2025 AEDT
Key Points
R&D Tax Incentive approval secured for Phase 3 program through FY2027
Three strategic partnerships inked, including a US$2M+ licensing deal
Completed A$2.17 million capital raising to fund Phase 3 preparations
Ethics approvals obtained; first patient dosing on track for Q4 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CMB
OPEN ARTICLE